Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human RO7502175 alone and with atezolizumab in advanced solid tumors
NL-OMON53546Phase 1Not yet recruiting
- Sponsor
- Genentech
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of RO7502175 and atezolizumab in Nonhematologic neoplasms, sponsored by Genentech. Primary endpoints: Incidence and nature of dose-limiting toxicities, Incidence and severity of adverse events and 3 more. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
RO7502175atezolizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON53546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53546.